CellCarta
ActiveCellCarta has been active since 2001 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €25.87M and a net result of €7.70M. Equity is growing by ~20% per year across the filed fiscal years. Its solvency ranks better than 43% of 187 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Checked score
Score 2025
94
/ 100
Excellent▼ -5 vs 2024
The score combines four axes. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability88▼-2
Solvency87▲+18
Growth82▼-2
Stability100
Bankruptcy probability, 12 months
0.3%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €2M at 30 days acceptable
Liquidity ample (current ratio 2.37 against 1.88 in 2024), but 57.2% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Eight signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
42.8%
Return on assets
12.7%
Age of the figures
8 mo
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 72
Relative position
BE, all sectors
reference
Sector 72
lower
← fewer bankruptcies
more bankruptcies →
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 09-06-2026, 52 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
52 d early
2024
56 d late
2023
33 d early
2022
31 d late
2021
41 d early
2020
65 d early
2019
15 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
14-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, full schema
Turnover
€79.88M▲ 7.9%
2024 · €74.03M
2018: €26.15M
2019: €27.54M
2020: €30.81M
2021: €42.83M
2022: €53.08M
2023: €58.62M
2024: €74.03M
2018 → 2025
EBIT margin
14.7%▲ 0.3pp
2024 · 14.3%
2018: 23.5%
2019: 20.3%
2020: 11.3%
2021: 9.0%
2022: 9.7%
2023: 6.0%
2024: 14.3%
2018 → 2025
Net result
€7.70M▼ 12.5%
2024 · €8.79M
2018: €4.36M
2019: €3.98M
2020: €2.36M
2021: €7.73M
2022: €-7.60M
2023: €860k
2024: €8.79M
2018 → 2025
Working capital
€27.87M▲ 27.4%
2024 · €21.88M
2018: €9.01M
2019: €11.07M
2020: €14.78M
2021: €9.02M
2022: €10.62M
2023: €13.95M
2024: €21.88M
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Turnover€42.83M-€53.08M▲ 23.9%€58.62M▲ 10.4%€74.03M▲ 26.3%€79.88M▲ 7.9%
Equity€16.11M-€8.51M▼ 47.2%€9.37M▲ 10.1%€18.17M▲ 93.8%€25.87M▲ 42.4%
Operating result€3.87M-€5.13M▲ 32.5%€3.54M▼ 30.9%€10.60M▲ 199%€11.71M▲ 10.5%
Net result€7.73M-€-7.60M€860k€8.79M▲ 922%€7.70M▼ 12.5%
Result per fiscal year
Operating resultNet result
After the dip in 2023 the operating result has climbed two years in a row; 2025 is 10% above 2024 and is the highest year so far.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €60.47M
Fixed assets
€12.20M▲ 10.7%
Current assets
€48.27M▲ 3.0%
Equity and liabilities €60.47M
Equity
€25.87M▲ 42.4%
Debt
€34.61M▼ 12.9%
The debt ratio falls from 68.6% to 57.2%: equity grows while debt is paid down.
Key figures and ratios
EBITDA
€14.35M▲
2024 · €12.73M
Cash flow
€10.33M▼
2024 · €10.92M
Solvency
42.8%▲
2024 · 31.4%
Current ratio
2.37▲
2024 · 1.88
Quick ratio
2.07▲
2024 · 1.63
Debt / equity
1.34▼
2024 · 2.19
ROE
29.8%▼
2024 · 48.4%
ROA
12.7%▼
2024 · 15.2%
Interest coverage
67.68▲
2024 · 37.14
Debt
€34.61M▼
2024 · €39.72M
Debt ≤ 1 year
€20.40M▼
2024 · €24.99M
Debt > 1 year
€1.09M▲
2024 · €224k
Income taxes
€2.75M▲
2024 · €1.49M
Staff costs
€23.06M▲
2024 · €20.23M
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€57.89M€60.47M▲
Fixed assets21/28€11.02M€12.20M▲
Intangible fixed assets21€3.61M€3.40M▼
Tangible fixed assets22/27€4.99M€6.11M▲
Land and buildings22€1.11M€1.32M▲
Plant, machinery and equipment23€2.64M€2.50M▼
Furniture and vehicles24€641k€841k▲
Leasing and similar rights25€597k€1.45M▲
Financial fixed assets28€2.41M€2.70M▲
Affiliated companies280/1€2.38M€2.66M▲
Participating interests280€2.38M€2.66M▲
Companies linked by participating interests282/3€30k€30k=
Participating interests282€30k€30k=
Other financial fixed assets284/8€3k€3k=
Amounts receivable and cash guarantees285/8€3k€3k=
Current assets29/58€46.87M€48.27M▲
Amounts receivable after more than one year29€6.18M€10.05M▲
Other amounts receivable291€6.18M€10.05M▲
Stocks and contracts in progress3€6.08M€5.97M▼
Stocks30/36€6.08M€5.97M▼
Raw materials and consumables30/31€2.34M€2.58M▲
Goods purchased for resale34€3.74M€3.39M▼
Amounts receivable within one year40/41€16.97M€21.86M▲
Trade receivables40€15.20M€20.83M▲
Other amounts receivable41€1.77M€1.03M▼
Current investments50/53€1.30M€1.30M=
Own shares50€1.30M€1.30M=
Cash at bank and in hand54/58€15.19M€7.29M▼
Deferred charges and accrued income490/1€1.14M€1.80M▲
Equity and liabilities
Total equity and liabilities10/49€57.89M€60.47M▲
Equity10/15€18.17M€25.87M▲
Contributions10/11€1.06M€1.06M=
Capital10€1.06M€1.06M=
Issued capital100€1.06M€1.06M=
Reserves13€17.11M€24.80M▲
Non-distributable reserves130/1€1.41M€1.41M=
Legal reserve130€106k€106k=
Own shares acquired1312€1.30M€1.30M=
Distributable reserves133€15.70M€23.40M▲
Amounts payable17/49€39.72M€34.61M▼
Amounts payable after more than one year17€224k€1.09M▲
Financial debts170/4€224k€1.09M▲
Leasing and similar obligations172€224k€1.09M▲
Amounts payable within one year42/48€24.99M€20.40M▼
Current portion of amounts payable after more than one year42€368k€346k▼
Financial debts43-€2.00M
Other loans439-€2.00M
Trade debts44€18.07M€10.86M▼
Suppliers440/4€18.07M€10.86M▼
Taxes, remuneration and social security45€5.63M€6.45M▲
Taxes450/3€2.50M€2.72M▲
Remuneration and social security454/9€3.12M€3.73M▲
Other amounts payable47/48€922k€746k▼
Accrued charges and deferred income492/3€14.51M€13.12M▼
Income statement
Code20242025
Operating income70/76A€80.82M€88.45M▲
Turnover70€74.03M€79.88M▲
Other operating income74€6.50M€8.57M▲
Non-recurring operating income76A€294k€0▼
Operating charges60/66A€70.22M€76.73M▲
Goods for resale, raw materials and consumables60€9.88M€9.72M▼
Purchases600/8€10.80M€9.61M▼
Change in stocks: decrease (increase)609€-921k€110k▲
Services and other goods61€37.79M€41.11M▲
Remuneration, social security and pensions62€20.23M€23.06M▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€2.13M€2.63M▲
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4€149k€9k▼
Other operating charges640/8€48k€51k▲
Non-recurring operating charges66A-€147k
Operating profit (loss)9901€10.60M€11.71M▲
Financial income75/76B€553k€808k▲
Recurring financial income75€553k€808k▲
Income from financial fixed assets750-€5k
Income from current assets751€158k€156k▼
Other financial income752/9€395k€647k▲
Financial charges65/66B€875k€2.07M▲
Recurring financial charges65€875k€2.07M▲
Debt charges650€343k€212k▼
Other financial charges652/9€533k€1.86M▲
Non-recurring financial charges66B€0-
Profit (loss) for the period before taxes9903€10.28M€10.45M▲
Income taxes67/77€1.49M€2.75M▲
Taxes670/3€1.98M€2.75M▲
Tax adjustments and reversals of tax provisions77€491k€0▼
Profit (loss) for the period9904€8.79M€7.70M▼
Profit (loss) for the period to be appropriated9905€8.79M€7.70M▼
Appropriation of the result
Profit (loss) to be appropriated9906€8.79M€7.70M▼
Transfer to equity691/2€8.79M€7.70M▼
To other reserves6921€8.79M€7.70M▼
Social balance
Average headcount (FTE)9087236.4242.7▲
The notes to these accounts (81 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
11-08
State Gazette act
Resignations & appointmentsGeneral meeting · Director resignation · Permanent representative8 facts ▸
State Gazette act
Resignations & appointments
General meeting · Director resignation · Permanent representative8 facts ▸
- General meeting, 13/05/2026
- Director resignation, KOCKX-CONSULTING BV (bestuurder)
- Permanent representative, Mark Kockx
- Director resignation, Maurice Tenney III (bestuurder)
- Director resignation, PwC Bedrijfsrevisoren BV (commissaris)
- Auditor appointment, PwC Bedrijfsrevisoren BV (commissaris)
- Permanent representative, Roel Boons
- Director reappointment, Maurice Tenney III (bestuurder)
09-06
NBB filing
Annual accounts filed
fiscal year 2025 · full schema
2025
31-12
Financial
Equity above €25MEq €25.87M ▲42.4%
3 profitable years in a row build equity to €25.87M.
25-09
NBB filing
Annual accounts filed
fiscal year 2024 · full schema · 56 days late
2024
31-12
Financial
Highest result since 2018net €8.79M ▲922%
Net result €8.79M, the highest in the series.
31-12
Financial
Equity above €10MEq €18.17M ▲93.8%
2 profitable years in a row build equity to €18.17M.
28-06
NBB filing
Annual accounts filed
fiscal year 2023 · full schema
2023
31-12
Financial
Back to profitnet €860k
Net result €860k after one loss-making year.
31-08
NBB filing
Annual accounts filed
fiscal year 2022 · full schema · 31 days late
2022
31-12
Financial
Weakest financial yearnet €-7.60M ▼198%
Net result drops to €-7.60M, the lowest in the series; recovery starts the following year.
20-06
NBB filing
Annual accounts filed
fiscal year 2021 · full schema
2021
27-05
NBB filing
Annual accounts filed
fiscal year 2020 · full schema
2020
16-07
NBB filing
Annual accounts filed
fiscal year 2019 · full schema
2019
31-12
Financial
Equity above €10MEq €10.82M ▲32.9%
2 profitable years in a row build equity to €10.82M.
03-06
NBB filing
Annual accounts filed
fiscal year 2018 · full schema
2018
07-06
NBB filing
Annual accounts filed
fiscal year 2017 · full schema
2017
09-06
NBB filing
Annual accounts filed
fiscal year 2016 · full schema
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
8 directors, no change since 2026
Maurice Tenney III
CurrentDirector · since 13-05-2026
13-05-2026
Maurice Tenney III: Resigned as Director
13-05-2026
Maurice Tenney III: Mandate renewed as Director
11-03-2026
Kockx-Consulting BV: Resigned as Director
30-06-2025
Anthony Mattacchione: Resigned as Director
06-02-2025
David Spaight: Resigned as Director
30-08-2023
Martin LeBlanc: Resigned as Director
30-08-2023
Martin LeBlanc: Resigned as Managing director
01-08-2019
HistoGeneX Holding NV: Resigned as Director
01-08-2019
Klinisch Bioloog Walter Verstrepen BVBA: Resigned as Director
10-05-2017
Simon Scharpé: Resigned as Director
Location & real-estate footprint
Registered office, Antwerpen · 3 establishment units since 2001
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Sint-Bavostraat 782610 AntwerpenGround area
2.3 ha
Building footprint
5,502 m²
Volume, LiDAR
52,794 m³
3 parcels, Flanders · tallest building 16.4 m, ±4 floors. Linked by address, not a title deed.
3 establishment units
CellCarta
since 20012.116.346.295
Logistics
since 20232.381.109.082
Sneeuwbeslaan 20, 2610 Antwerpen
since 20252.381.108.785
3 parcels
Flanders
3
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 11051B0041/00W000 | Flanders | 1.5 ha | 1 · 3,529 m² | 16.4 m · 4 fl. |
| 11051C0160/00L006 | Flanders | 4,612 m² | 1 · 972 m² | 9.3 m · 2 fl. |
| 11463D0411/00L002 | Flanders | 2,678 m² | 1 · 1,001 m² | 7.6 m · 2 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1 · via establishment units: 2
3 of 3 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Statutory auditor
2 auditors| BV PwC BedrijfsrevisorenCurrent Statutory auditor · represented by Roel Boons | 11-08-2026 → present |
Show 1 earlier auditors
| Lieven van Brussel Statutory auditor | - → 04-04-2018 |
Structure & network
Connections & network
2 connected companiesNetwork connections
Shared address
→
Shared address
→
Public money · subsidies and aid
Flemish government
2022 to 2025 · 9 entries · 235,088 EUR awarded · 190,052 EUR paid| Year | Entries | awarded | paid |
|---|---|---|---|
| 2025 | 3 | 2,556 EUR | 2,556 EUR |
| 2024 | 2 | 2,503 EUR | 88,503 EUR |
| 2023 | 2 | 10,565 EUR | 96,565 EUR |
| 2022 | 2 | 219,464 EUR | 2,428 EUR |
Schemes
Innovatieprojecten in de context van een speerpuntcluster
Vlaams opleidingsverlof (VOV)
European research
3 projects · 182,933 EUR EU contributionProgrammes
HORIZON
h2020
Projects
TUMOUR ACTIVATED IMMUNOTHERAPY FOR SOLID TUMOURS (TAIST)
Protease‐guided tumor targeting tools to revolutionize cancer diagnosis and treatment.
Modulation of glycolytic flux as a new approach for treatment of atherosclerosis and plaque stabilization: a multidisciplinary study
Similar companies · same sector, comparable size
Flanders Make
BE 0860.286.268
Lommel · Eq €26.03M
LabCorp
BE 0465.578.521
Mechelen · Eq €26.04M
CENTRE DE RECHERCHES METALLURGIQUES - CENTRUM VOOR RESEARCH IN DE METALLURGIE
BE 0406.015.373
Brussel · Eq €25.26M
Fondation Fournier Majoie pour l'Innovation
BE 0886.551.096
Ukkel · Eq €25.03M
Swave
BE 0781.441.007
Leuven · Eq €26.81M
Of 1,175 companies in sector 72109 we hold annual accounts for 712. 130 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPublic limited company
Founded23-04-2001
Fiscal year end31-12
Activities, NACEBEL
72109Other research and development on natural sciences
73100
85141
86901Human health activities
86910Medical imaging and medical laboratories
Sources
Crossroads Bank for EnterprisesNational Bank · 24 filingsAddress and cadastre registers
Data from official sources, last processed on 13-09-2026. Scores and ratios are computed by Checked and are not a credit decision.
Contact details
3 entriesE-mail:info@histogenex.com
Phone:+32 3 502 05 00
Fax:+32 3 230 02 65